Chardan's Equity Research Team Publishes in a Peer-reviewed Journal

NEW YORK, Dec. 18, 2018 /PRNewswire/ -- Chardan, a global investment bank, announced today that the peer-reviewed journal, Human Gene Therapy Clinical Development, published a perspective authored by analysts in the firm's equity research department. The article, entitled "Traditional Approaches for Company Valuation Are Flawed for Valuing In Vivo Gene Therapy Companies," is the first in a three-part series focused on valuing in vivo gene therapy companies.

Advertisement

The publication, led by Chardan's Head of Healthcare Research, Dr. Gbola Amusa, CFA, focuses on the underpinnings of company valuation and why widely-used approaches are limited in valuing in vivo gene therapy companies. The report examines a case study on AveXis, a registration-stage gene therapy company acquired by Novartis, to illustrate points on the valuation of breakthrough innovations that will have broader applicability throughout the in vivo gene therapy space.

Advertisement

"We're examining different types of valuation methodologies that should help investors recognize the true potential of some of the most exciting emerging technologies the world has ever seen," said Amusa. "Traditional valuation methods used across dozens of sectors have limitations when evaluating gene therapies and are a reason why many overlooked the potential of AveXis, our former top pick in the sector, before the company was acquired for $8.7 billion earlier this year, more than 14x its $600 million IPO valuation two years earlier."

Co-authoring the report and the team that works directly with Dr. Amusa for his genetic medicines coverage includes:

• Dr. Kip Bitok earned his PhD in Biochemistry Cellular and Molecular Biology from the Johns Hopkins University School of Medicine and did his postdoctoral work at The Rockefeller University, where he studied the discovery of bioactive molecules from environmental DNA.
• Dr. Taylor Feehley earned her PhD in Immunology from the University of Chicago, where she studied the role of the intestinal microbiome in regulating food allergies, for which she was named to the 2016 Forbes 30-Under-30 list in Science.
• Dr. Natalya Gertsik earned her PhD in Biochemistry, with a focus on Alzheimer's disease drug development, from Weill Cornell University. After completion of her PhD, she worked as a consultant at McKinsey, serving clients in the pharmaceutical, health insurance, and social sector industries.
• Dr. Geulah Livshits earned her PhD from the Rockefeller University and did her postdoctoral work at Memorial Sloan Kettering Cancer Center, where she used CRISPR and RNAi to study the role of chromatin regulators in pancreatic cancer.

To receive a copy of the report please visit the publisher's website for Human Gene Therapy.

About Chardan

Chardan is an independent global investment bank specializing in healthcare, SPACs and emerging growth companies. Our range of services includes capital raising, merger and acquisition advisory, strategic advisory, equity research, corporate access and institutional trading. Headquartered in New York City, Chardan is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: FINRA, SIPC, NASDAQ and the NYSE Arca, Inc.

Learn more about Chardan: www.chardan.com

Company Contact: Emily Levine, [email protected] (646) 465-9018

Media Contact:Thomas J. Rozycki Jr., Prosek [email protected](646) 818-9208

View original content:http://www.prnewswire.com/news-releases/chardans-equity-research-team-publishes-in-a-peer-reviewed-journal-300768000.html

SOURCE Chardan Capital Markets, LLC